Minimal access breast surgery ‘valid’ option for early breast cancer
Minimal access breast surgery offers comparable long-term outcomes to conventional surgery for women with stage 0–III breast cancer, show the results of a propensity-matched, retrospective cohort study.
Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors
The use of PI3K inhibitors for the treatment of cancer is associated with a high risk for developing cutaneous adverse events, suggests a meta-analysis published in JAMA Oncology.
High IL-6, CRP may predict increased frailty after breast cancer chemotherapy
Clinically fit older women with early breast cancer are more likely to experience chemotherapy-induced decline in frailty if they have high pretreatment levels of IL-6 and CRP, research shows.
Incidental sinoatrial node irradiation may increase AF risk in lung cancer
Incidental irradiation of the sinoatrial node during lung cancer chemoradiotherapy may be associated with an increased risk for atrial fibrillation and death, research suggests.
Extended anastrozole benefits dependent on tumor characteristics
Extending adjuvant aromatase inhibition to beyond 5 years of sequential therapy should not be recommended to all postmenopausal women with hormone receptor-positive early breast cancer, but some subgroups may benefit, research suggests.
Analysis points to FOLFIRINOX chemotherapy benefits for metastatic pancreatic cancer
FOLFIRINOX chemotherapy may offer better survival than gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma, suggests a comparative effectiveness study published in JAMA Network Open.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Fertility preservation not linked to higher breast cancer relapse, mortality risk
Women who undergo hormonal or nonhormonal fertility preservation procedures following breast cancer diagnosis are not at increased risk for relapse or breast cancer-specific mortality, Swedish study findings indicate.
ARROW update demonstrates first-line pralsetinib benefit for advanced RET fusion-positive NSCLC
Updated findings from the ARROW trial show that pralsetinib has “robust efficacy” for the first-line treatment of locally advanced or metastatic, RET fusion-positive, non-small-cell lung cancer, the investigators say.
Large proportion of global cancer deaths, DALYs attributable to modifiable risk factors
Modifiable risk factors accounted for almost half of the global cancer mortality and disability-adjusted life–years in 2019, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.
Trastuzumab deruxtecan-related ILD/pneumonitis characterized
A pooled analysis of nine early-phase trials of trastuzumab deruxtecan monotherapy has identified an incidence of drug-related interstitial lung disease/pneumonitis of 15.4%.
